Agilent Technologies, Inc.
A · NYSE
A · NYSE
Agilent Technologies sells analytical measurement instruments, laboratory software, consumables and related services used in research, testing, quality control and diagnostics. Its customers include pharmaceutical and biotechnology companies, chemical and materials producers, academic and government laboratories, and clinical laboratories. The business combines recurring service and consumables revenue with instrument sales, while its major operating areas include Life Sciences and Applied Markets, CrossLab services, and Diagnostics and Genomics. The supplied evidence does not state the approximate contribution of each segment. Agilent generates $6.9 billion of annual revenue and $1.3 billion of net income in FY2025, versus $6.5 billion and $1.3 billion in FY2024.
Agilent fell $1.34, or 0.95%, from $140.54 on July 28 to $139.20 on August 4. The stock weakened for three consecutive sessions through July 31, reaching $138.37, before rebounding to $139.80 on August 3 and giving back part of that recovery the following day. The supplied evidence identifies no Agilent-specific earnings release, guidance update, analyst action, contract, or other catalyst during the period. The listed research coverage concerns other healthcare and life-sciences companies, including Thermo Fisher, Stryker, and Revvity. No broader market or sector performance is provided, so the week’s modest decline cannot be attributed to a documented external driver.
